MTOR and breast cancer: Based on the results of the BOLERO-2 trial, the mTOR inhibitor Everolimus (RAD001) has been approved for use in postmenopausal women with hormone-receptor positive (HR+)/Her-2− advanced BC, refractory to non-steroidal aromatase inhibitors [15].